CANN vs CVS
Trees Corp. (Colorado) and CVS Health Corp., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CANN | CVS |
|---|---|---|
| Revenue | $18.1M | $402.1B |
| Net income | $-7.1M | $1.8B |
| Gross margin | 36.2% | 45.0% |
| Net margin | −39.0% | 0.4% |
| Return on equity | −216.1% | 2.3% |
| Diluted EPS | −$0.06 | $1.39 |
| Dividend / share | · | $2.66 |
| Payout ratio | · | 192.1% |
| Free cash flow | · | $7.8B |
| Equity | $148,159 | $75.2B |
| Net debt / equity | 95.41× | 0.69× |
| Current ratio | 0.32× | 0.84× |
| Revenue CAGR 5y | 59.9% | 8.4% |
| Profit CAGR 5y | · | −24.4% |
CVS bills 22168.5× the revenue of CANN, and CANN closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | CANN | CVS |
|---|---|---|
| FY2023 | $18.1M | $357.8B |
| FY2022 | $13.4M | $322.5B |
| FY2021 | $5.9M | $292.1B |
| FY2020 | $2.4M | $268.7B |
| FY2019 | $3.7M | $256.8B |
| FY2018 | $1.7M | $194.6B |
| FY2017 | $3.5M | $184.8B |
| FY2016 | $3.0M | $177.5B |
| FY2015 | $1.8M | $153.3B |
| FY2014 | $240,206 | $139.4B |
Bottom line
| Fiscal year | CANN | CVS |
|---|---|---|
| FY2023 | $-7.1M | $8.3B |
| FY2022 | $-9.5M | $4.3B |
| FY2021 | $-8.9M | $8.0B |
| FY2020 | $-7.7M | $7.2B |
| FY2019 | $-15.5M | $6.6B |
| FY2018 | $-17.0M | $-594.0M |
| FY2017 | $-8.2M | $6.6B |
| FY2016 | $-10.2M | $5.3B |
| FY2015 | $-8.8M | $5.2B |
| FY2014 | $-6.9M | $4.6B |
12 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2023 | −$357,757,863,120 | CVS |
| FY2022 | −$322,453,555,458 | CVS |
| FY2021 | −$292,105,072,801 | CVS |
| FY2020 | −$268,703,616,296 | CVS |
| FY2019 | −$256,772,333,654 | CVS |
| FY2018 | −$194,577,262,744 | CVS |
| FY2017 | −$184,782,477,925 | CVS |
| FY2016 | −$177,543,018,018 | CVS |
| FY2015 | −$153,288,237,022 | CVS |
| FY2014 | −$139,366,759,794 | CVS |
| FY2012 | −$123,119,995,860 | CVS |
| FY2011 | −$107,079,997,195 | CVS |
CVS has reported the higher revenue in every one of these 12 fiscal years. The gap has widened since the earliest year compared.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2023 | −41.4 pp | CVS |
| FY2022 | −71.8 pp | CVS |
| FY2021 | −152.4 pp | CVS |
| FY2020 | −324.9 pp | CVS |
| FY2019 | −424.9 pp | CVS |
| FY2018 | −976.7 pp | CVS |
| FY2017 | −237.0 pp | CVS |
| FY2016 | −343.9 pp | CVS |
| FY2015 | −501.8 pp | CVS |
| FY2012 | −494.0 pp | CVS |
CVS has kept the higher net margin in every one of these 10 fiscal years.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
CANN's net margin has been more volatile than CVS's over the 10 comparable fiscal years — 258.7 percentage points of standard deviation against 1.1.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
CVS led in net margin in every one of the 10 comparable fiscal years — a structural lead, not a recent swing.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
CANN's return on equity has been more volatile than CVS's over the 7 comparable fiscal years — 121.8 percentage points of standard deviation against 4.1.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
CVS led in return on equity in every one of the 7 comparable fiscal years — a structural lead, not a recent swing.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.